RARECast
Podcast autorstwa RARECast - Czwartki
548 Odcinki
-
Leveraging Technology to Empower Patients and Decentralize Clinical Trials
Opublikowany: 20.10.2022 -
Equipping The Next-Generation Rare Disease Patient Advocate
Opublikowany: 13.10.2022 -
How a Family Raced from Diagnosis to Experimental Gene Therapy in Three Years
Opublikowany: 6.10.2022 -
How One Advocate Went from Losing His Hearing to Being Heard
Opublikowany: 29.09.2022 -
Building a Pipeline of Therapies to Treat Rare Mineralization Disorders
Opublikowany: 22.09.2022 -
Advancing an Oral Alternative to Infused and Injected Therapies for HAE
Opublikowany: 15.09.2022 -
Embracing the Promise of Patient-Centered Biotechnology
Opublikowany: 8.09.2022 -
Learning to Live with Loss
Opublikowany: 1.09.2022 -
Using Cryptocurrency to Tap into the Wisdom of Crowds
Opublikowany: 25.08.2022 -
A Therapy for a Rare Neurodegenerative Disease Moves Towards Regulatory Review
Opublikowany: 18.08.2022 -
Transforming the Treatment of Neuromuscular Diseases with Next-Gen Oligonucleotides
Opublikowany: 11.08.2022 -
Teaching the Immune System to Let Medicines Do Their Job
Opublikowany: 4.08.2022 -
Designing Clinical Trials with the Patient in Mind
Opublikowany: 28.07.2022 -
Keeping Clinical Trials Running Smoothly
Opublikowany: 21.07.2022 -
A Vision for Patient-Centric Gene Therapy Development
Opublikowany: 14.07.2022 -
Using Genetic Testing to Address Disparities in Care for Kidney Disease
Opublikowany: 7.07.2022 -
Why Reforms to the Accelerated Approval Pathway Threaten Rare Disease Drug Development
Opublikowany: 30.06.2022 -
A Longstanding Academic-Nonprofit Collaboration Gives Rise to an ALS Drug Company
Opublikowany: 16.06.2022 -
Targeting Regulatory RNA to Upregulate Gene Expression to Treat Rare Diseases
Opublikowany: 9.06.2022 -
Developing a New Approach to Treat Rare, Autoimmune Conditions
Opublikowany: 2.06.2022
RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.